Nasdaq · CIK 0000949858
ACHV ACHIEVE LIFE SCIENCES, INC.
Insider trading from SEC Form 4. Last filing 6 d ago. Close $7.41 on Oct 9, 2026, +180% from the 52-week low and -13% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ACHVOct 9, 2026 · close 7.41
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ACHIEVE LIFE SCIENCES, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | Richard Alistair Stewart Chief Executive Officer sell | $378k 129,501 shares | -36% | +45% from low-46% from high | |
| 43Moderate | Mark K Oki Chief Financial Officer sell | $146k 50,060 shares | -28% | +45% from low-46% from high | |
| 27Weak | Jaime Xinos Chief Commercial Officer sell | $58k 20,854 shares | -22% | +41% from low-47% from high | |
| 33Weak | Cindy Jacobs President & CMO sell | $77k 27,629 shares | -19% | +41% from low-47% from high | |
| 41Moderate | Thomas Braxton King Executive Chairman sell | $387k 139,858 shares | -31% | +41% from low-47% from high | |
| 31Weak | Jerry Wan Principal Accounting Officer sell | $39k 14,070 shares | -30% | +41% from low-47% from high | |
| 31Weak | Richard Alistair Stewart Chieve Executive Officer buy | $29k 10,000 shares | +20% | - | |
| 43Moderate | Mark K Oki Chief Financial Officer buy | $29k 10,000 shares | - | - |
Transactions
The last 56 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Benjamin Halladay Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | 6 d ago |
| Oct 5, 2026 | Benjamin Halladay Chief Financial Officer | AGrant or award Restricted Stock Unit (RSU)derivative | +200,000 | $0.00 | $0 | 200,000 | 6 d ago |
| Jan 28, 2026 | Jerry Wan Principal Accounting Officer | AGrant or award Stock Option (right to buy)derivative | +70,300 | $0.00 | $0 | 70,300 | Jan 30, 2026 |
| Jan 28, 2026 | Richard Alistair Stewart Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +645,000 | $0.00 | $0 | 645,000 | Jan 30, 2026 |
| Jan 28, 2026 | Craig Donnelly Chief Operations Officer | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Jan 30, 2026 |
| Jan 28, 2026 | Jaime Xinos Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Jan 30, 2026 |
| Jan 28, 2026 | Mark K Oki Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Jan 30, 2026 |
| Jan 28, 2026 | Mark Lawrence Rubinstein Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | Jan 30, 2026 |
| Dec 4, 2025 | Erik Atkisson Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Dec 8, 2025 |
| Oct 1, 2025 | Craig Donnelly Chief Operations Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Oct 3, 2025 |
| Sep 18, 2025 | Richard Alistair Stewart Chief Executive Officer | MOption exercise Common Stock | +297,500 | $0.00 | $0 | 358,376 | Sep 22, 2025 |
| Sep 18, 2025 | Mark K Oki Chief Financial Officer | MOption exercise Common Stock | +168,000 | $0.00 | $0 | 178,000 | Sep 22, 2025 |
| Sep 18, 2025 | Richard Alistair Stewart Chief Executive Officer | SOpen-market sale Common Stock | -129,501 | $2.92 | $378k | 228,875 | Sep 22, 2025 |
| Sep 18, 2025 | Mark K Oki Chief Financial Officer | SOpen-market sale Common Stock | -50,060 | $2.92 | $146k | 127,940 | Sep 22, 2025 |
| Sep 18, 2025 | Mark K Oki Chief Financial Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -168,000 | $0.00 | $0 | 0 | Sep 22, 2025 |
| Sep 18, 2025 | Richard Alistair Stewart Chief Executive Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -140,000 | $0.00 | $0 | 0 | Sep 22, 2025 |
| Sep 18, 2025 | Richard Alistair Stewart Chief Executive Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -157,500 | $0.00 | $0 | 0 | Sep 22, 2025 |
| Sep 4, 2025 | Mark K Oki Chief Financial Officer | AGrant or award Performance Restricted Stock Unitderivative | -168,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Richard Alistair Stewart Chieve Executive Officer | AGrant or award Performance Restricted Stock Unitderivative | -140,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Jerry Wan Principal Accounting Officer | MOption exercise Common Stock | +34,100 | $0.00 | $0 | 46,764 | Sep 8, 2025 |
| Sep 4, 2025 | Thomas Braxton King Executive Chairman | MOption exercise Common Stock | +455,000 | $0.00 | $0 | 455,000 | Sep 8, 2025 |
| Sep 4, 2025 | Cindy Jacobs President & CMO | MOption exercise Common Stock | +110,000 | $0.00 | $0 | 143,214 | Sep 8, 2025 |
| Sep 4, 2025 | Jaime Xinos Chief Commercial Officer | MOption exercise Common Stock | +69,000 | $0.00 | $0 | 95,286 | Sep 8, 2025 |
| Sep 4, 2025 | Jerry Wan Principal Accounting Officer | SOpen-market sale Common Stock | -14,070 | $2.77 | $39k | 32,694 | Sep 8, 2025 |
| Sep 4, 2025 | Richard Alistair Stewart Chieve Executive Officer | AGrant or award Performance Restricted Stock Unitderivative | -157,500 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Jaime Xinos Chief Commercial Officer | SOpen-market sale Common Stock | -20,854 | $2.77 | $58k | 74,432 | Sep 8, 2025 |
| Sep 4, 2025 | Thomas Braxton King Executive Chairman | SOpen-market sale Common Stock | -139,858 | $2.77 | $387k | 315,142 | Sep 8, 2025 |
| Sep 4, 2025 | Cindy Jacobs President & CMO | SOpen-market sale Common Stock | -27,629 | $2.77 | $77k | 115,585 | Sep 8, 2025 |
| Sep 4, 2025 | Thomas Braxton King Executive Chairman | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -455,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Jaime Xinos Chief Commercial Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -49,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Jerry Wan Principal Accounting Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -24,500 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Cindy Jacobs President & CMO | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -84,000 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Sep 4, 2025 | Jerry Wan Principal Accounting Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -9,600 | $0.00 | $0 | 38,400 | Sep 8, 2025 |
| Sep 4, 2025 | Jaime Xinos Chief Commercial Officer | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -20,000 | $0.00 | $0 | 80,000 | Sep 8, 2025 |
| Sep 4, 2025 | Cindy Jacobs President & CMO | MOption exercise Performance Restricted Stock Unit (PRSU)derivative | -26,000 | $0.00 | $0 | 104,000 | Sep 8, 2025 |
| Jun 6, 2025 | Thomas Sellig director | AGrant or award Stock Option (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 10, 2025 |
| Jun 6, 2025 | Kristen B. Slaoui director | AGrant or award Stock Option (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 10, 2025 |
| Jun 6, 2025 | Nancy R. Phelan director | AGrant or award Stock Option (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 10, 2025 |
| Jun 6, 2025 | Thomas Braxton King Executive Chairman | AGrant or award Stock Option (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 10, 2025 |
| Jun 6, 2025 | Stuart Duty director | AGrant or award Stock Option (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 10, 2025 |
| Jun 6, 2025 | Bridget A Martell director | AGrant or award Stock Option (right to buy)derivative | +31,500 | $0.00 | $0 | 31,500 | Jun 10, 2025 |
| Mar 17, 2025 | Richard Alistair Stewart Chieve Executive Officer | POpen-market purchase Common Stock | +10,000 | $2.86 | $29k | 60,876 | Mar 19, 2025 |
| Mar 17, 2025 | Mark K Oki Chief Financial Officer | POpen-market purchase Common Stock | +10,000 | $2.89 | $29k | 10,000 | Mar 19, 2025 |
| Jan 28, 2025 | Cindy Jacobs President & CMO | AGrant or award Performance Restricted Stock Unit (PRSU)derivative | +130,000 | $0.00 | $0 | 130,000 | Jan 30, 2025 |
| Jan 28, 2025 | Jaime Xinos Chief Commercial Officer | AGrant or award Performance Restricted Stock Unit (PRSU)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 30, 2025 |
| Jan 28, 2025 | Jerry Wan Principal Accounting Officer | AGrant or award Performance Restricted Stock Unit (PRSU)derivative | +48,000 | $0.00 | $0 | 48,000 | Jan 30, 2025 |
| Jan 13, 2025 | Thomas Braxton King Executive Chairman | AGrant or award Performance Restricted Stock Unit (PRSU)derivative | +455,000 | $0.00 | $0 | 455,000 | Jan 14, 2025 |
| Jan 13, 2025 | Kristen B. Slaoui director | AGrant or award Stock Option (right to buy)derivative | +47,250 | $0.00 | $0 | 47,250 | Jan 14, 2025 |
| Jan 13, 2025 | Nancy R. Phelan director | AGrant or award Stock Option (right to buy)derivative | +47,250 | $0.00 | $0 | 47,250 | Jan 14, 2025 |
| Jan 13, 2025 | Richard Alistair Stewart Chieve Executive Officer | AGrant or award Performance Restricted Stock Unit (PRSU)derivative | +157,500 | $0.00 | $0 | 157,500 | Jan 14, 2025 |
| Jan 13, 2025 | Jaime Xinos Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jan 14, 2025 |
| Jan 13, 2025 | Richard Alistair Stewart Chieve Executive Officer | AGrant or award Stock Option (right to buy)derivative | +67,500 | $0.00 | $0 | 67,500 | Jan 14, 2025 |
| Jan 13, 2025 | Thomas Braxton King Executive Chairman | AGrant or award Stock Option (right to buy)derivative | +195,000 | $0.00 | $0 | 195,000 | Jan 14, 2025 |
| Dec 6, 2024 | Mark K Oki Chief Financial Officer | AGrant or award Common Stock Options (right to buy)derivative | +72,000 | $0.00 | $0 | 72,000 | Dec 9, 2024 |
| Dec 6, 2024 | Jaime Xinos Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Dec 9, 2024 |
| Dec 6, 2024 | Mark K Oki Chief Financial Officer | AGrant or award Performance Restricted Stock Unit (PRSU)derivative | +168,000 | $0.00 | $0 | 168,000 | Dec 9, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Erik AtkissonChief Legal Officer
- Craig DonnellyChief Operations Officer
- Stuart Dutydirector
- Benjamin HalladayChief Financial Officer
- Cindy JacobsPresident & CMO
- Thomas Braxton KingExecutive Chairman
- Bridget A Martelldirector
- Mark K OkiChief Financial Officer
- Nancy R. Phelandirector
- Mark Lawrence RubinsteinChief Medical Officer
- Thomas Selligdirector
- Kristen B. Slaouidirector
- Richard Alistair StewartChief Executive Officer
- Jerry WanPrincipal Accounting Officer
- Jaime XinosChief Commercial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.